CoChat

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial

Open access
Heise, Tim, Zijlstra, Eric, Nosek, Leszek, Rikte, Tord, Haahr, Hanne · 2017 · Diabetes, Obesity and Metabolism
Cited by 78

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate the pharmacological characteristics of faster‐acting insulin aspart (faster aspart) compared with insulin aspart ( IAsp ) during continuous subcutaneous insulin infusion ( CSII ). Methods: In this randomized, double‐blind, crossover trial, 48 men and women aged 18 to 64 years with type 1 diabetes mellitus ( T1DM ) received faster aspart and IAsp as a 0.15 U/kg bolus dose via CSII , on top of a basal rate (0.02 U/kg/h), in a glucose clamp setting (target 5.5 mmol/L). Results: After a CSII bolus dose, the pharmacokinetic/pharmacodynamic profiles for faster aspart were left‐shifted compared with those for IAsp . For faster aspart vs IAsp , the early glucose‐lowering effect (area under the curve for glucose infusion rate [ GIR ] 0‐30min ) was approximately 2‐fold higher (least squares means 24.9 vs 11.4 mg/kg; estimated ratio faster aspart/ IAsp 2.18, 95% confidence interval [CI] [1.33; 5.04]; P = .002), onset of glucose‐lowering effect (time to early 50% of maximum GIR ) occurred 11.1 minutes earlier (41.1 vs 52.3 minutes; 95% CI faster aspart – IAsp [−15.4; −6.9]; P <.001), and offset of glucose‐lowering effect (time to late 50% of maximum GIR ) occurred 24.0 minutes earlier (214.7 vs 238.7 minutes; 95% CI [−38.9; −9.1]; P =.002). Likewise, significantly greater early exposure and significantly earlier onset and offset of exposure were observed for faster aspart vs IAsp . Faster aspart and IAsp were both well tolerated. Conclusions: In patients with T1DM using CSII , faster aspart better mimics the endogenous prandial insulin secretion and action than does IAsp . Faster aspart therefore has the potential to provide clinical benefits over current rapid‐acting insulins in the insulin pump setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12803

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 78

Metadata

Authors
Heise, T., Zijlstra, E., Nosek, L., Rikte, T., & Haahr, H.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-11-14
Volume
19
Issue
2
Pages
208-215
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2529414368
Cited by
78
References
9
FWCI
10.97
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial. https://app.cochat.ai/papers/10.1111/dom.12803
The paper
Heise, T., Zijlstra, E., Nosek, L., Rikte, T., & Haahr, H. (2017). Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12803

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.